Sheet	1	of	1
OHEEL	1	OI	1

01	Substitute Form PTO-1449 P(MEDITED)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16596-018001	Application No. 10/076,074
Information Disclos	closure Statement	Applicant Matthew C. Coffey, et al.		
JUN 1		neets if necessary)	Filing Date February 15, 2002	Group Art Unit 1642

DEMARKS 1.90			U.S. Patent	t Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
•	AA						
	AB						
	AC						!
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AL							
	AM							
	AN							
	AO							
	AP							

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner Initial	Desig. ID	Document					
86C:	AQ	Bryson, J.S. and D.C. Cox, "Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia", Cancer Immunol. Immunother. 26: 132-138 (1988)					
	AR						
	AS						
	AT						

Examiner Signature Baoquen Li	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if next communication to applicant.	
\	Substitute Disclosure Form (PTO-1449)

Sheet	1	- 6	1
)11¢¢f	1	of	1

Pubstitute Form PTO-1449 (Modified)	U.S. Department of Commerce. Patent and Trademark Office		Application No. 10/076,074	
	hucaur	Applicant Matthew C. Coffey, et al.		
(Use several sho	eets if necessary)	Filing Date February 15, 2002	Group Art Unit 1642	

			U.S. Patent	Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH					'	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or				lation
Initial	ID Number Date Patent Office Class	Subclass	Yes	No				
	AI							
	AJ							
	AK							
	AL							
	AM							

	Other Documents (include Author, Title, Date, and Place of Publication)							
Examiner Initial	Desig. ID	Document						
300	AN	Steele, T. A. and Cox, D. C., "Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin", Cancer Biotherapy 10(4): 307-315 (1995).						
	AO	Rayter, S. I. et al., "p21 ^{ras} mediates control of IL-2 gene promoter function in T cell activation", EMBO Journal 11(12): 4549-4556 (1992).						
	AP	Baldari, C. T., et al., "Interluekin-2 promoter activation in T-cells expressing activated Ha-ras", J. Biological Chemistry 267(7): 4289-4291 (1992).						
	AQ	Umezawa K. et al., "Isolation of a new vinca alkaloid from the leaves of <i>Ervantimia microphylla</i> as an inhibitor of ras functions", Anticancer Research 14: 2413-2418 (1994).						
V	AR	Umezawa K. et al., "Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice", Drugs Exptl. Clin. Res. 22(2): 36-40 (1996).						

	1		
Examiner Signature	7	Date Considered /	
Basquer	1	Date Considered	Hov 4
EXAMINER: Initials citation considered. Dr.	w line through citation if no	t in conformance and not	considered. Include copy of this form with
next communication to applicant./			outline in the second s
			Substitute Disclosure Form (PTO-1449)